The research consortium, Translational 沙巴体育 Consortia (TRC) for Chikungunya virus, was formed by the?沙巴体育?Institute of Virology,?沙巴体育?Academy of Higher Education in collaboration with the 沙巴体育 Centre for Genetic Engineering and Biotechnology (ICGEB, New Delhi), the Institute of Life Sciences (ILS, Bhubaneshwar), the All India Institute of Medical Sciences (AIIMS, Bhubaneshwar), the Post-Graduate Institute of Medical Education and 沙巴体育 (PGIMER, Chandigarh), and the?Topiwala?National Memorial Hospital (TNMC) and BYL Nair Charitable Hospital, Mumbai) as partner institutes. The Department of Biotechnology, Government of India, has supported this research study through BIRAC (Biotechnology Industry 沙巴体育 Assistance Council).?Major objectives of this research consortia are to establish a biobank of circulating Chikungunya viral strains in the country, along with a serum bank of na?ve, early stage acute infection and convalescent samples to understand the differences in the immune status. To understand the modulation in the immune responses of chikungunya-infected individuals; the inflammatory cytokines, chemokines, and growth factor levels will be measured at different stages of the infection along with T-cell and B-cell phenotyping. With the proposed objectives, the consortia will be able to sketch a complete immune profiling of acute and chronic infections. Patients coming to the participatory hospitals will be followed up with regular collection of samples. The circulating viral strains isolated from infected individuals will be sequenced to identify subtypes and mutations within the Indian subcontinent and subsequently used to develop standardized high throughput assays for viral quantification and infectivity. An animal model of Chikungunya will also be developed to understand the disease progression in acute and chronic stages of infection and correlated with symptoms in humans.?